- Home
- COLL vs KBDC Comparison
COLL vs KBDC Comparison
Compare COLL & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- KBDC
- Stock Information
- Founded
- COLL 2002
- KBDC 2021
- Country
- COLL United States
- KBDC United States
- Employees
- COLL N/A
- KBDC N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- KBDC
- Sector
- COLL Health Care
- KBDC
- Exchange
- COLL Nasdaq
- KBDC Nasdaq
- Market Cap
- COLL 1.1B
- KBDC 1.2B
- IPO Year
- COLL 2015
- KBDC N/A
- Fundamental
- Price
- COLL $33.35
- KBDC $16.70
- Analyst Decision
- COLL Strong Buy
- KBDC Buy
- Analyst Count
- COLL 5
- KBDC 5
- Target Price
- COLL $43.80
- KBDC $17.30
- AVG Volume (30 Days)
- COLL 486.5K
- KBDC 88.0K
- Earning Date
- COLL 02-20-2025
- KBDC 02-15-2025
- Dividend Yield
- COLL N/A
- KBDC 5.39%
- EPS Growth
- COLL 757.11
- KBDC N/A
- EPS
- COLL 2.16
- KBDC N/A
- Revenue
- COLL $599,245,000.00
- KBDC N/A
- Revenue This Year
- COLL $13.20
- KBDC $193.84
- Revenue Next Year
- COLL $17.63
- KBDC $15.95
- P/E Ratio
- COLL $15.42
- KBDC N/A
- Revenue Growth
- COLL 9.62
- KBDC N/A
- 52 Week Low
- COLL $28.39
- KBDC $15.69
- 52 Week High
- COLL $42.29
- KBDC $17.22
- Technical
- Relative Strength Index (RSI)
- COLL 62.31
- KBDC N/A
- Support Level
- COLL $32.29
- KBDC N/A
- Resistance Level
- COLL $33.99
- KBDC N/A
- Average True Range (ATR)
- COLL 1.29
- KBDC 0.00
- MACD
- COLL 0.51
- KBDC 0.00
- Stochastic Oscillator
- COLL 87.40
- KBDC 0.00
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.